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Abstract
Background: The aim of this study was to investigate the presence of MMP-14 and MMP-2 during human ovarian
follicular development using immunohistochemistry, and the activity of MMP-2 in follicular fluid using zymography.
Methods: Ovarian tissue collected from the archives of the Department of Pathology was examined and medical
records and histopathology were reviewed. Follicular fluids were collected at the IVF-department and analyzed
using zymography.
Results: MMP-14 and MMP-2 were increasingly found in the growing follicles and MMP-2 was highly expressed in
the corpus luteum. Pro-MMP-2 was present in follicular fluid of IVF-patients.
Conclusions: The presence of MMP-14 and MMP-2 during human ovarian follicular development from the primordial
follicle to the tertiary follicle and corpus luteum is confirmed, as was indicated by earlier animal studies following
stimulation with gonadotrophins.
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Background
Proteins of the matrix metalloproteinase (MMP) family
are involved in degrading the extracellular matrix in nor-
mal physiological processes such as embryonic develop-
ment, reproduction, and tissue remodeling, as well as in
disease processes such as wound healing, arthritis and
cancer [1]. Most MMP’s are secreted as inactive propro-
teins, which are activated when cleaved by extracellular
proteinases. For this study, we focused on MMP-14 and
MMP-2.
MMP-14 (former MT1-MMP) is a member of the
membrane-type MMP (MT-MMP) subfamily [2]. These
proteins are expressed at the cell surface rather than se-
creted, and contain a transmembrane domain. Apart from
functioning as a gelatinase itself, MMP-14 also cleaves
pro-MMP-2 (72 kD) into its active 66 kD form [2,3].
Holmbeck et al. described MMP-14 deficient mice, espe-
cially showing malfunctioning of the connective tissue of
ligaments, tendons and joint capsules. MMP-14 was found
to have a postnatal effect. The mice show no sexual mat-
uration and age early with generalized fibrosis, loss of hair,
joint contractures and reduced mobility [1,4].
Mice deficient in MMP-2 show normal development
and reproduction, but have specific altered cellular func-
tions spontaneously or on experimental challenge [1].
Although MMP’s seem to play an important role in ovu-
lation, the role of MMP’s may be taken over by other
proteins, as the studies with MMP-inhibitors in rodents
on corpus luteum formation demonstrates [5].
Animal research in rodents, cattle and primates sug-
gests a role for MMP-14 and MMP-2 in ovarian follicle-
formation and follicle-rupture [6,7]. In normal follicle
growth in humans, the follicle expands to 400 times its
size in approximately two weeks before timely ovulation.
This requires coordinated remodeling of the basement
membrane of the follicle and the surrounding extra-
cellular matrix. Gelatinase activity by MMP-2 is found in
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follicular fluid on the inside of the follicle and higher
activity is found in PolyCystic Ovary Syndrome (PCOS)
patients compared to women with normal ovulation [8].
MMP-2 also plays a role in corpus luteum formation in
humans. However, the sizes of these immunohistoche-
mical studies in humans are rather small with a total of
78 patients [9-12].
Little is known about the exact role of MMP-14 and
MMP-2 in human follicular growth and development, as
tissue is not readily available. Therefore, the role of MMP-
14 and MMP-2 in ovarian physiology is difficult to investi-
gate. Furthermore, it is impossible to test the same follicle
while growing and after ovulation. Even animal research is
hampered by sampling restrictions of follicles and the fact
that sampling in developing follicles might induce MMP-
activity due to the repeated trauma of the follicle.
By studying MMP-14 and MMP-2 with immunohisto-
chemistry in normal ovaries, the presence of these pro-
teins in follicles in various stages of development can be
evaluated. In this study we present data on the expression
of MMP-14 and MMP-2 in human follicular development,
and zymographic activity of MMP-2 in follicular fluid.
Methods
From the Database of the Clinical Pathological Labora-
tory patients were selected with the search term “normal
ovary”. From these patients paraffin-embedded blocks
that were stored at room temperature within the time-
frame 2009–2010 were collected from the archives. Of
30 consecutive patients the medical records were stud-
ied. Only premenopausal patients, who were not using
hormonal therapy (such as oral contraceptives and levo-
norgestrel containing IUD) were included. All patients
had a regular cycle. Patients with ovarian malignancies
and benign ovarian tumors which are known to have
MMP-expression (e.g. endometriosis) were excluded.
One ovary was normal and was removed because of a
mucinous borderline tumor of the other ovary. Two pa-
tients had a teratoma, one patient had a serous cystade-
noma, two patients had a mucinous cystadenoma, one
patient had a simple cyst, one a pseudocyst and one a
functional cyst. All 9 ovaries showed normal histopath-
ology before and after revision, the ovaries with torsion
showed no lysis or haemorrhagia. As well as histopath-
ology, clinical patient data were reviewed.
Table 1 Histopathological characteristics of ovaries used for immunohistochemical studies
Age Histopathological diagnosis Treatment Remarks
32 Teratoma Laparoscopic cystectomy
55 Simple cyst Salpingo-oophorectomy
33 Serous cystadenoma Cystectomy
35 Pseudocyst Salpingo-oophorectomy
36 Functional cyst Laparoscopic cystectomy Torsion
34 Teratoma Laparoscopic cystectomy Torsion
38 Mucinous cystadenoma and Brenner tumour Laparoscopic ovariectomy
34 Mucinous cystadenoma Cystectomy
48 Normal ovary Staging laparotomy Mucinous borderline tumor other ovary
Table 2 IHC scores in ovarian follicular development
Histopathological diagnosis OSE Primord.
Follicle
PF TF granulosa
cells
TF theca
cells
CL granulosa
cells
CL theca
cells
Atretic
follicle
Teratoma 17+/19*- ++/** +/*
Simple cyst ++/** −/−
Serous cystadenoma ++/* +++/*
Pseudocyst ++/* 2+/9- +/*
Functional cyst (torsion) +/* ++/** +/*
Teratoma (torsion) 4+/6-
Mucinous cystadenoma
and Brenner tumour
++/* 2+/1-
Mucinous cystadenoma + /-
Normal ovary +/* +/*
IHC = ImmunoHistoChemistry, OSE = Ovarian Surface Epithelium, Primord. = Primordial, PF = Primary/Growing Follicle, TF = Tertiary Follicle, CL = Corpus Luteum, - = no
MMP-2 or 14 expression, + = MMP-2 expression, * = MMP-14 expression, ++ = moderate MMP-2 expression, ** = moderate MMP-14 expression, +++ = strong MMP-2 expression,
the number before the symbols -, + or * indicates the number of follicles found, if no number is indicated, the number is one.
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Sections (3 μm) were deparaffinised in xylene and rehy-
drated in graded alcohol. Immunohistochemistry was done
in one run with omitting the primary antibody as a nega-
tive control.
Each slide contained positive controls for MMP’s, con-
sisting of placenta. Endogenous peroxidase was blocked
with 3% H2O2 and Normal Goat Serum 5%. After each
incubation step, slides were washed two times with Phos-
phate Buffered saline (PBS).
For MMP-14 we used a polyclonal antibody, anti-human
MMP-14 rabbit IgG (Thermo Scientific), diluted 1:20 for
60 minutes at room temperature [2].
As primary antibody for MMP-2, a monoclonal anti-
body was used, anti-human MMP-2 mouse IgG (clone
A-Gel vc2, Thermo Scientific), diluted 1:10 [13]. Incuba-
tion was overnight at 4° Celsius.
As secondary antibody for both proteins poly-HRP-
GAM/R/R IgG (Immunologic, Duiven, the Netherlands)
was used during 60 minutes at room temperature. Stain-
ing was done with diaminobenzidine for two times 5
minutes using the Power Vision protocol. Slides were
counterstained with hematoxylin.
A scoring system was used in which the intensity of the
scoring (−absent, +weak, ++moderate, +++strong staining)
and the number of positive follicular cells (0 = 0%, 1 = 1-
25%, 2 = 26-50%, 3 = 51-75%, 4 = 76-100% of cells) were
incorporated [14]. Stromal staining was recorded, but not
incorporated in the scoring system. Follicles in different
phases of development were scored according to our scor-
ing system.
Two investigators scored all slides (JL, MCV). If they
disagreed, consensus was found by consulting the gyne-
copathologist (AvdW).
Figure 1 Representative slide of Ovarian surface epithelium for
MMP-2 10×20 magnification showing high pericellular expression
of MMP-2.
Figure 2 Representative slide of Primordial follicle for MMP-2
10×20 magnification showing MMP-2 expression in most cells.
Figure 3 Representative slide of Ovarian surface epithelium for
MMP-14 10×20 magnification showing diffuse cytoplasmatic
expression of MMP-14.
Figure 4 Representative slide of Primordial follicle for MMP-14
10×20 magnification showing MMP-14 expression in some cells
and not in other cells.
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Of 9 consecutive IVF-ICSI patients at the Centre for
Reproductive Medicine at St. Elisabeth Hospital, Tilburg,
the Netherlands, follicular fluid was collected at the time
of IVF puncture. Also, cyst fluid of a patient with a be-
nign cyst was collected. Of these patients the following
variables were collected: age, duration of infertility, indi-
cation for IVF-ICSI, number of oocytes and the result of
treatment in terms of pregnancy.
Follicular fluid was collected in 50 ml tubes, of which the
first tube was used for zymographic analysis. At the time of
puncture the total amount of fluid per tube and the appear-
ance of the follicular fluid, the number of oocytes in that
tube and the total number of oocytes were described.
Follicular fluid was frozen at −20° until time of analysis.
The protocol was reviewed by our Medical Ethical
Committee that confirmed, that it did not need formal
evaluation. IVF-ICSI patients were informed by a leaflet
describing this investigation.
Zymography was performed according to [15]. In
short, 10% SDS-PAGE gels containing 2 mg gelatin/ml
were loaded with 10 μl follicular fluid in non-reducing
sample buffer 1:1. After electrophoresis, gels were washed
twice with 2.5% Triton X-100 (BDH Chemicals) for
15 min. After a final wash in 0.05 M Tris HCl, pH 8.0 con-
taining 5 mMCaCl2 and 0.01% Triton X-100 gels were
incubated in 0.05 M Tris HCl, pH 8.0 containing 5 mM
CaCl2, 0.01% Triton X-100 and 5 mM ZnCl2 at 37% for
4–72 h. After incubation gels were stained with 0.5%
(w/v) Coomassie Brilliant Blue R250 in a mixture of
methanol, acetic acid and MilliQ (5:1:4 resp.) After
destaining in 5:1:4 methanol/acetic acid/MilliQ, zones
of enzymatic activity appeared as clear white bands
against a blue background.
Figure 6 Representative slide of overview Tertiary follicle for
MMP-2 5×10 magnification.
Figure 8 Representative slide of detail Tertiary follicle for MMP-2
10×20 magnification showing intense expression of MMP-2
especially at the inner layer of the follicle.
Figure 5 Representative slide of Primary follicle for MMP-2
10×20 magnification showing intense expression of MMP-2 in
most cells.
Figure 7 Representative slide of Primary follicle for MMP-14
10×20 magnification showing expression of MMP-14 in especially
the inner layer of the follicle.
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Gels were incubated in the presence of 20 mM EDTA, an
inhibitor of MMP’s, to indicate the specificity of the assay.
Because of the low number of patients for both immu-
nohistochemistry as well as zymography formal statis-
tical analysis was not performed.
Results
We examined histopathological slides of 9 ovaries of pa-
tients, that were removed because of benign, functional or
simple cysts, two of which underwent torsion. For histo-
pathological characteristics of the ovaries see Table 1.
We found mainly cytoplasmatic staining for MMP-14
and mainly pericellular staining for MMP-2. The MMP-
14 staining was more diffuse than the MMP-2 staining.
In Table 2 the main results of immunohistochemistry
are summarized. Figures 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
and 12 show examples of relevant sections.
In most primordial follicles, no MMP-14 protein is
detected, but MMP-2 is present.
In one patient, some cells of some primordial follicles did
express MMP-14 and some cells did not show MMP-14
expression.
Stromal staining for both MMP-14 and MMP-2 around
primordial follicles was diffuse and weak and therefore not
classified as positive.
In small primary/growing follicles the expression of
both MMP-14 and MMP-2 is already more positive than
in primordial follicles. The concentration of both pro-
teins is highest at the inner layer of the granulosa cell
layer next to the follicular fluid compartment.
High MMP-14 and MMP-2 expression in the inner
layer of the granulosa cells is still present in one of the
tertiary follicles we examined. In the other tertiary
follicle the high expression at the inner layer of both
Figure 9 Representative slide of overview Tertiary follicle for
MMP-14 5×10 magnification.
Figure 10 Representative slide of Corpus luteum for MMP-2
10×20 magnification with intense expression of MMP-2.
Figure 12 Representative slide of Corpus luteum for MMP-14
10×20 magnification with less intense expression of MMP-14.
Figure 11 Representative slide of detail Tertiary follicle for
MMP-14 10×20 magnification also showing intense expression
at the inner layer of the follicle for MMP-14.
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proteins seemed less. We also observed high MMP-2
expression in the stromal cells of the ovary adjacent to
the tertiary follicle, while little stromal MMP-14 expres-
sion was found.
In the corpus luteum MMP-2 is present with intense
staining, especially in the inner layer of the granulosa cells,
the outer layer had little expression of MMP-2. MMP-14
staining is less in both in the granulosa and theca cell layer.
The atretic follicle had diffuse MMP-14 and MMP-2 ex-
pression, which was not cellular. Since it did not have the
typical pattern of cytoplasmatic staining for MMP-14 and
pericellular staining for MMP-2, we did not classify it as
positive. Ovarian surface epithelium does have expression of
both proteins, which is the same in each slide, but in some
specimens the staining was more intense than in others.
We collected follicular fluid of 9 patients and one cyst
fluid of a benign cyst. IVF/ICSI characteristics of donors
of follicular fluid are summarized in Table 3. Of these
10 patients zymographic evaluation of follicle fluid was
performed. A typical example of a zymogram is depicted
in Figure 13. In all patients pro-MMP-2 is present
co-migrating with recombinant MMP-2. However, no
separate band for activated MMP-2 was found in these
zymograms. Patient 1 and patient 8 became pregnant,
in patient 1 a high concentration of pro-MMP-2 was
found. Patient 8 did not seem to differ from the other
patients. The benign cystic fluid had very little MMP-2.
In the IVF patients also bands with gelatinase-activity
with higher molecular weight were observed. They were
less in density and may represent MMP-9.
Discussion
The present study used immunohistochemistry to deter-
mine that MMP-14 and MMP-2 are present in various
stages of human follicular development, which is con-
sistent with the results of previous animal studies using
FISH and zymography following gonadotrophic stimula-
tion [6,16,17]. The present study also used zymography
to demonstrate the presence of pro-MMP-2 in follicular
fluid from IVF patients.
For both MMP-14 and MMP-2, a large proportion of the
follicular and the ovarian surface epithelial cells were found
to be positive, and the more advanced the development of
the follicle, the greater the staining intensity (Table 2). Our
findings in the corpora lutea appear to conflict with the
findings of Manase et al. [12], though only two corpora
lutea were examined in the present study and Manase
et al. did not study follicles prior to ovulation. With respect
to stromal staining, we found a different staining pattern
for MMP-2 than the pattern observed by Lind et al. [11].
MMP-2 expression was found in stromal cells in the
vicinity of the tertiary follicle and not around primordial
follicles in the present study, while Lind et al. found stro-
mal staining around the primordial follicles [11].
Table 3 IVF/ICSI characteristics of donors of follicular fluid used for zymography
Age
(years)
Indication Primary/secundary
infertility
Time infertility
(years)
IVF/ICSI Dose FSH Amount
follicular fluid
Number oocytes
in tube
Total number
oocytes
Pregnant
28 Irregular cycle Primary 7 IVF 225 41 2 5 +
30 PCOS Primary 3 IVF 187.5 42 0 4 -
32 eci Primary 3 IVF 225 36 3 8 -
40 Male factor Secundary 2 ICSI 100 34 5 10 -
25 Male factor Primary 1 ICSI 112.5 34 4 8 -
36 Male factor Secundary 3 Half/half 150 34 6 10 -
34 Male factor Primary 2 ICSI 150 30 5 14 -
31 Male factor Primary 2 ICSI 112.5 25 2 5 +
37 Male factor Secundary 1 ICSI 300 39 7 19 -
63 Benign cyst n.a. 80 - - n.a.
IVF = In Vitro Fertilisation, ICSI = Intracytoplasmatic Sperm Injection, FSH = Follicle Stimulating Hormone, n.a. = not applicable, PCOS = PolyCystic Ovary Syndrome.
Figure 13 Zymogram of follicular fluids at IVF. Note that this figure was composed of different zymograms.
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A difference was seen between the immunohistochem-
ical staining patterns for MMP-14 and those for MMP-
2: the former exhibit mostly cytoplasmatic and the latter
mostly pericellular staining. The presence of MMP-2 in
follicular fluid cannot be established by immunohis-
tochemistry, though it has been demonstrated using
zymography in animals, ELISA of pooled follicular
fluids from IVF patients [8-10,18] and, as in the present
study, zymography of such fluids.
Previously, in addition to immunohistochemistry and
zymography, mRNA expression of MMP-14 and MMP-2
was used to study ovarian physiology, but only in the
corpora lutea [12].
During its development, the human follicle increases
in size by a factor 400 (illustrated by Figures 2-4 to 8
and 11). This requires extensive basement-membrane
and extracellular matrix remodeling around the follicle,
which continues during and after ovulation in the corpus
luteum. Various studies indicate that MMP-14 plays a
crucial role in this growth process; in particular, this is
borne out by the phenomenon that MMP-14-deficient
mice do not reproduce, whereas MMP-2-deficient mice
do. Most of the present study’s findings show the pres-
ence of both MMP’s in follicular development. However,
in all but one of the patients, no MMP-14 expression in
primordial follicles was found but MMP-2 expression
was observed; however, in a single patient – inexplicably –
some primordial follicles exhibited MMP-14 and MMP-2
expression. This is inconsistent with the reported cru-
cial role of MMP-14 in follicle growth. A MMP-2 stimu-
lating pathway not involving MMP-14 has not been
described in this context.
Strikingly, most MMP-14 and MMP-2 expression was
found at the inner surface of the follicle, rather than at
the follicular interface with the ovarian stroma. It may
be reasonable to expect greater MMP expression at that
interface, where remodeling of the extracellular matrix
occurs. Interestingly, MMP-14 is known to respond not
only to chemical but also physical stimuli [19,20]. It may
be that the increasing pressure in the growing follicle
stimulates MMP-14 expression and activity.
Two shortcomings of this study are its small sample
size and its cross-sectional design. The latter meant that
it was impossible to determine the relative ages of differ-
ent primordial follicles in the same patient. An ideal
study would follow a large number of follicles through
their entire maturation process, but in practice this is
impossible.
Our zymography results are comparable with those of
other studies [8,12]. In the benign cystic fluid, little
MMP-2 was found. MMP-2 is 72 kD in its inactive form
and 66 kD following activation by MMP-14. The SDS in
the zymography gels partly unfolds the inactive enzyme,
rendering it active and detectable [21]. As zymography
for MMP-2 is always performed under non-reducing
conditions, the actual height of the bands is altered in
most cases to 68 kD for the inactive form and 62 kD for
the active form. In equine follicular fluid, also most of
the MMP-2 that is detected by zymography is inactive
[9]. In human corpora lutea extracts, the highest con-
centration of active MMP-2 is found in the late luteal
phase [12]. In our IVF follicular fluids, we found no acti-
vated MMP-2, as was described by Lind et al. [11].
MMP-2 is detected in the follicular fluid, intracel-
lularly in the follicle, and can be found extracellularly
in the stroma, where it is probably recycled rapidly. A
disadvantage of immunohistochemistry is that it only
detects bound MMP-2. Furthermore, the monoclonal
antibody used in this study probably does not detect
differences between inactive and active MMP-2 [13].
Conclusions
In conclusion, it has been demonstrated that MMP-14
and MMP-2 are expressed in developing human ovarian
follicles and that there is MMP-2 present in the follicular
fluid. These results are consistent with the patterns re-
vealed by mRNA expression and zymography in numer-
ous animal studies and a few human studies.
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